Abiopharma

(19% Negative) Atara Biotherapeutics, Inc. (ATRA) Announces Clinical Trial Timeline Adjustment

(75% Positive) REPLIMUNE GROUP, INC. (REPL) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(99% Neutral) EPIZYME, INC. (EPZM) Announces Executive Changes

(99% Neutral) ObsEva SA (company was delisted NASDAQ) (OBSV) Announces 2022 Annual General Meeting

(10% Negative) Instil Bio, Inc. (TIL) Announces Delay in patients Trials for cancer Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Efficacy Assessment

(99% Neutral) IVERIC bio, Inc. (ISEE) Files Form 8-K

(99% Neutral) AMGEN INC (AMGN) Announces Regulatory Update

(10% Negative) BridgeBio Pharma, Inc. (BBIO) Announces Delay in million Trials for rare pediatric diseases Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations

(99% Neutral) Agios Pharmaceuticals, Inc. (AGIO) Announces Executive Changes

(99% Neutral) Vertex Pharmaceuticals (VRTX) Announces Regulatory Update